Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE

Patients treated at the Hôpital Nord de Marseille for at least one smoking-related pathology (atheroma, chronic bronchitis, non-progressive cancer > 5 years) or with eligibility criteria for lung cancer screening (inclusion criteria in the NLST or NELSON studies or American recommendations) Interventional study with minimal risks and constraints, with evaluation of lung cancer prevalence; immunological, blood inflammatory and microbiota profileDetermine the maximum clinical, radiological, and biological phenotyping completeness rate following the implementation of a new lung cancer screening care pathway with multidimensional clinical, radiological, and biological phenotyping capabilities

Inclusion Criteria:Age 45- 75 years andMedical follow-up for a smoking-related pathology :atheromachronic obstructive pulmonary disease / emphysemahistory of non evolving cancer > 5 years among: ENT, lung, breast, cervical, excreto-urinary cervix, excreto-urinary tract, bladder, esophagus, stomach, pancreas, liver, kidney, chronic myeloid leukemia chronic myeloid leukemia,daily smoking for at least 10 years prior to the disease OrNLST inclusion criteria:Age 55 - 74 yearsCumulative smoking ≥ 30 pack-yearsactive or quit for less than 15 years OrInclusion criterion in NELSON:Age 50-75 yearsSmoking:> 15 cigarettes/D for more than 25 years or> 10 cigarettes /D for more than 30 yearsActive smoking or cessation < 10 years OrNew American recommendations :Age 50 - 80 yearsSmoking ≥20 PAActive or weaned <15 yearsExclusion Criteria:history of cancer < 5 years (except carcinoma in situ of the uterine cervix, basal cell skin carcinoma basal cell carcinoma of the skin and prostate cancer with undetectable PSA)Symptoms of lung cancer (unintentional weight loss > 7 kg in 1 year, hemoptysis)known history of pulmonary nodule with specialized follow-uphistory of pulmonary fibrosis or pulmonary hypertensionpatient under guardianship or curatorshipactive pulmonary parenchymal infectionsevere cardiac or respiratory insufficiency (rest dyspnea)patient not affiliated to the social security system (beneficiary or beneficiary's right)Patient deprived of libertyPerformance status (WHO) 2, 3 or 4Pregnant or breastfeeding women